Bivalirudin is a safe and effective anticoagulant in the percutaneous treatment of complex infrainguinal disease

Journal of Endovascular Therapy

Volumn 17, Issue 1, 2010, Pages 37-38

  Walker, Craig M ^a  

^a Cardiovascular Institute of the South   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; HEPARIN; HIRULOG; PENTASACCHARIDE; THROMBIN; ANTICOAGULANT AGENT; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ANGIOGRAPHY; ARTERY DISEASE; BLEEDING; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; INFRAINGUINAL DISEASE; MORBIDITY; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS; THROMBUS; VASCULARIZATION; ANGIOPLASTY; CHEMICALLY INDUCED DISORDER; HOSPITALIZATION; ISCHEMIA; PERIPHERAL VASCULAR DISEASE; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; STENOSIS, OCCLUSION AND OBSTRUCTION; TREATMENT OUTCOME;

ANGIOPLASTY; ANTICOAGULANTS; CONSTRICTION, PATHOLOGIC; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; ISCHEMIA; PEPTIDE FRAGMENTS; PERIPHERAL VASCULAR DISEASES; RECOMBINANT PROTEINS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77952525668     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1583/09-2810C.1     Document Type: Note

References (17)

1. Shammas NW, Lemke JH, Dippel EJ, et al. In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. J Invasive Cardiol. 2003;15:242-246.
2. Shammas NW. Complications in peripheral vascular interventions: emerging role of direct thrombin inhibitors. J Vasc Interv Radiol. 2005;16(2 Pt 1):165-171. (Pubitemid 40322290)
3. Smith FB, Rumley A, Lee AJ, et al. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol. 1998;100:758-763.
4. McDermott MM, Green D, Greenland P, et al. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol. 2003;92:194-199.
5. Robless PA, Okonko D, Lintott P, et al. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2003;25:16-22. (Pubitemid 36527595)
6. Allie DE, Hall P, Shammas NW, et al. The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): in-hospital and 30-day results. J Invasive Cardiol. 2004;16:651-656.
7. Shammas NW, Shammas GA, Jerin M, et al. In-hospital safety and effectiveness of bivalirudin in percutaneous peripheral interventions: data from a real-world registry. J Endovasc Ther. 2010;17:31-36.
8. Burgess JK, Chong BH. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol. 1997;58:279-285.
9. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251-256.
10. Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003;15:611-616.
11. Shammas NW. Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev. 2005;23:345-360.
12. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein llb/llla blockade vs heparin and planned glycoprotein llb/llla blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292:696-703.
13. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post infarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952-959.
14. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa during percutaneous coronary intervention; the REPLACE-2 randomized trial. JAMA. 2003;289:853-863.
15. Shah PB, Ahmed WH, Ganz P, et al. Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions. J Am Coll Cardiol. 1997;30:1264-1269. (Pubitemid 27501444)
16. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 2002;359:294-302.
17. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-2216.